Decline in opioid prescribing after federal rescheduling of hydrocodone products

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II. Methods: We used 2013 to 2015 data for 9 202 958 patients aged 18 to 64 from a large nationally representative commercial health insurance program to assess the temporal trends in the monthly rate of opioid prescribing. Results: HCP prescribing decreased by 26% from June 2013 to June 2015; the rate of prescriptions for any opioid decreased by 11%. Prescribing of non-hydrocodone schedule III opioids increased slightly while prescribing of non-hydrocodone schedule II opioids and tramadol was stable. Absolute decreases in HCP prescribing rates were larger in patients being treated for cancer (-2.26% vs -0.7% for non-cancer patients, P < 0.0001) and in those with high comorbidities (-2.13% vs -0.55% for those with no comorbidity, P < 0.0001). Differences in the absolute and relative changes in HCP prescribing rates among states were large; for example, a relative decrease of 46.7% in Texas and a 12.7% increase in South Dakota. The variation in HCP prescribing attributable to the state of residence increased from 6.6% in 2013 to 8.7% in 2015. Conclusions: The 2014 federal policy was associated with a decrease in rates of HCP and total opioid prescribing. The large decrease in the rates of HCP prescribing for patients with actively treated cancer may represent an unintended consequence.

Original languageEnglish (US)
JournalPharmacoepidemiology and Drug Safety
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Hydrocodone
Opioid Analgesics
Appointments and Schedules
Comorbidity
Tramadol
Health Insurance
Prescriptions
Neoplasms

Keywords

  • Laws
  • Opioids
  • Pharmacoepidemiology
  • Public policy

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

@article{fe57e709da804e65b1be7429cdf66e84,
title = "Decline in opioid prescribing after federal rescheduling of hydrocodone products",
abstract = "Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II. Methods: We used 2013 to 2015 data for 9 202 958 patients aged 18 to 64 from a large nationally representative commercial health insurance program to assess the temporal trends in the monthly rate of opioid prescribing. Results: HCP prescribing decreased by 26{\%} from June 2013 to June 2015; the rate of prescriptions for any opioid decreased by 11{\%}. Prescribing of non-hydrocodone schedule III opioids increased slightly while prescribing of non-hydrocodone schedule II opioids and tramadol was stable. Absolute decreases in HCP prescribing rates were larger in patients being treated for cancer (-2.26{\%} vs -0.7{\%} for non-cancer patients, P < 0.0001) and in those with high comorbidities (-2.13{\%} vs -0.55{\%} for those with no comorbidity, P < 0.0001). Differences in the absolute and relative changes in HCP prescribing rates among states were large; for example, a relative decrease of 46.7{\%} in Texas and a 12.7{\%} increase in South Dakota. The variation in HCP prescribing attributable to the state of residence increased from 6.6{\%} in 2013 to 8.7{\%} in 2015. Conclusions: The 2014 federal policy was associated with a decrease in rates of HCP and total opioid prescribing. The large decrease in the rates of HCP prescribing for patients with actively treated cancer may represent an unintended consequence.",
keywords = "Laws, Opioids, Pharmacoepidemiology, Public policy",
author = "Mukaila Raji and Kuo, {Yong Fang} and Deepak Adhikari and Jacques Baillargeon and James Goodwin",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/pds.4376",
language = "English (US)",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Decline in opioid prescribing after federal rescheduling of hydrocodone products

AU - Raji, Mukaila

AU - Kuo, Yong Fang

AU - Adhikari, Deepak

AU - Baillargeon, Jacques

AU - Goodwin, James

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II. Methods: We used 2013 to 2015 data for 9 202 958 patients aged 18 to 64 from a large nationally representative commercial health insurance program to assess the temporal trends in the monthly rate of opioid prescribing. Results: HCP prescribing decreased by 26% from June 2013 to June 2015; the rate of prescriptions for any opioid decreased by 11%. Prescribing of non-hydrocodone schedule III opioids increased slightly while prescribing of non-hydrocodone schedule II opioids and tramadol was stable. Absolute decreases in HCP prescribing rates were larger in patients being treated for cancer (-2.26% vs -0.7% for non-cancer patients, P < 0.0001) and in those with high comorbidities (-2.13% vs -0.55% for those with no comorbidity, P < 0.0001). Differences in the absolute and relative changes in HCP prescribing rates among states were large; for example, a relative decrease of 46.7% in Texas and a 12.7% increase in South Dakota. The variation in HCP prescribing attributable to the state of residence increased from 6.6% in 2013 to 8.7% in 2015. Conclusions: The 2014 federal policy was associated with a decrease in rates of HCP and total opioid prescribing. The large decrease in the rates of HCP prescribing for patients with actively treated cancer may represent an unintended consequence.

AB - Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II. Methods: We used 2013 to 2015 data for 9 202 958 patients aged 18 to 64 from a large nationally representative commercial health insurance program to assess the temporal trends in the monthly rate of opioid prescribing. Results: HCP prescribing decreased by 26% from June 2013 to June 2015; the rate of prescriptions for any opioid decreased by 11%. Prescribing of non-hydrocodone schedule III opioids increased slightly while prescribing of non-hydrocodone schedule II opioids and tramadol was stable. Absolute decreases in HCP prescribing rates were larger in patients being treated for cancer (-2.26% vs -0.7% for non-cancer patients, P < 0.0001) and in those with high comorbidities (-2.13% vs -0.55% for those with no comorbidity, P < 0.0001). Differences in the absolute and relative changes in HCP prescribing rates among states were large; for example, a relative decrease of 46.7% in Texas and a 12.7% increase in South Dakota. The variation in HCP prescribing attributable to the state of residence increased from 6.6% in 2013 to 8.7% in 2015. Conclusions: The 2014 federal policy was associated with a decrease in rates of HCP and total opioid prescribing. The large decrease in the rates of HCP prescribing for patients with actively treated cancer may represent an unintended consequence.

KW - Laws

KW - Opioids

KW - Pharmacoepidemiology

KW - Public policy

UR - http://www.scopus.com/inward/record.url?scp=85038869676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038869676&partnerID=8YFLogxK

U2 - 10.1002/pds.4376

DO - 10.1002/pds.4376

M3 - Article

C2 - 29271049

AN - SCOPUS:85038869676

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

ER -